Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients Bernard Lawrence Marini, Sung Won Choi, Craig Alan Byersdorfer, Simon Cronin, David G. Frame Biology of Blood and Marrow Transplantation Volume 21, Issue 5, Pages 809-820 (May 2015) DOI: 10.1016/j.bbmt.2014.10.027 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
Biology of Blood and Marrow Transplantation 2015 21, 809-820DOI: (10 Biology of Blood and Marrow Transplantation 2015 21, 809-820DOI: (10.1016/j.bbmt.2014.10.027) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Mechanism of statin immunomodulation in GVHD [17,55-58,60,61]. Treg indicates regulatory T cell; LFA1, leukocyte function-associated antigen-1; ICAM, intercellular adhesion molecule; CIIA, MHC class II transactivator; TCR, T cell receptor; MHCII, MHC complex class II; PP, pyrophosphate. Biology of Blood and Marrow Transplantation 2015 21, 809-820DOI: (10.1016/j.bbmt.2014.10.027) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions